[Focus] The hospital was named by the Medical Insurance Bureau because it "reported not to collect"!

On December 14, Tibet issued the "Notice on Issues Concerning National Centralized Procurement of Drugs Reporting and Procurement", which notified medical institutions that reported a volume of zero during the third batch of centralized procurement procurement cycles organized by some countries, involving 40 A hospital
.

To be honest, this situation is indeed surprising when centralized procurement has moved towards "normalization and institutionalization
.

" Today, there is such a bold medical institution? !

Therefore, the relevant departments could not help but not be angry! Tibet’s notification pointed out that since the state’s organization of centralized drug procurement, individual medical institutions in the Tibet Autonomous Region have severely decoupled from reporting and procurement, and there is even a problem that the proportion of agreed procurement completions is zero, which has seriously affected the quality and quality of centralized drug procurement in Tibet and the whole country.
Credibility
.

At the same time, the municipal medical security bureaus are required to attach great importance to the above-mentioned problems and take effective measures to rectify and reform in a timely manner

So, the national procurement has reported volume, but the procurement volume is zero, how much "privacy" is behind it?

One is that some medical institutions do not have a good understanding of volume procurement

One is that some medical institutions do not have a good understanding of volume procurement

Over the years, the government has tried many ways to solve the problem of poor and expensive medical treatment
.

Focusing on the "problem that expensive is a medicine", measures such as the highest retail price of controlled drugs, the purchase and sale markup rate of controlled medical institutions, the implementation of differential markup rates, the prohibition of discounts, the control of prescriptions and the average cost of drugs, have been adopted to reduce drug prices.

On November 14, 2018, the fifth meeting of the Central Comprehensive Deepening Reform Committee reviewed and approved the "National Organization of Drug Centralized Procurement Pilot Program", which clarified the overall thinking of state organization, alliance procurement, and platform operation
.

On November 15, 2018, with the approval of the Central Committee for Comprehensive Deepening of Reform, the state organized a pilot program for centralized drug procurement.
The pilot areas covered 11 cities in Beijing, Tianjin, Shanghai, Chongqing, Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi’an.
(Hereinafter referred to as 4+7 cities)
.

On December 10, 2019, the National Medical Insurance Administration issued the "Opinions on Doing a Good Job in Current Drug Price Management", clearly deepening the reform of the centralized drug procurement system, and insisting on "specialized procurement, linkage of volume and price, and integration of recruitment and procurement".
Direction, prompting drug prices to return to a reasonable level
.

The so-called quantity purchase means that the required purchase quantity will be announced in the bidding announcement.
In the bidding process, in addition to the price, you must also consider whether you can afford the corresponding production energy
.

And how does this "quantity" come from? According to the procurement policy with volume, all medical institutions participating in the centralized procurement are required to forecast and agree on the annual procurement volume based on 70% of the average procurement volume in the previous 1-3 years
.

The reason is that the annual purchase volume is agreed upon in accordance with 70% of the average purchase volume in previous years.

However, some medical institutions do not recognize the government's institutional arrangements, so they are arbitrary when reporting the amount, careless when signing the contract, and not paying attention to the implementation
.

Second, there are obvious problems with the reporting volume.

Second, there are obvious problems with the reporting volume.

The medical insurance department lacks guidance and supervision

The medical insurance department lacks guidance and supervision

According to the 40 medical institutions notified by Tibet this time (in fact, it is not 40 medical institutions, but involves 40 product regulations to purchase drugs), the general hospital of Tibet Military Region has 1 product regulation, and 6 county-level hospitals involve 19 product regulations.
, 1 community health service center has 1 product code, and 8 township health centers have 19 product codes
.

The problem is very obvious in terms of the product specifications and purchase volume of the drugs submitted for purchase

As a local medical insurance department, it should also provide guidance and monitoring of the procurement volume reported by medical institutions, and promptly remind and point out any abnormalities, especially when signing the agreement, or it will cause trouble for the next step.

.

At the same time, medical institutions that have reported but failed to purchase should be reminded in a timely manner.

Third, there is a congenital "deficiency" in volume purchases

Third, there is a congenital "deficiency" in volume purchases

It can be reflected from the Tibet notification that the drug procurement reports of medical institutions are "untrue", and the phenomenon of centralized procurement is not only a problem in Tibet, but exists in many parts of the country
.

Of course, the main reason for the false report is that medical institutions do not pay attention to it, do not understand the "quantity" in quantity procurement, lack the spirit of contract, and always think that the enterprise signing is a one-paper agreement (according to the understanding, the quantity procurement contract or the online contract, Not even a piece of paper), it can be implemented or not implemented.

But in fact, there is indeed a congenital “deficiency” in volume purchases, that is, it is impossible to accurately predict the amount of drugs used in medical services in advance, because for a medical institution, it is never possible to predict what disease the patient will have and how many people there will be.
Will get sick, how many people will go to your hospital for treatment after getting sick
.

Therefore, there is a lot of uncertainty in volume procurement
.

The official notification that the actual purchase volume of a certain drug after centralized procurement is significantly higher than the agreed purchase volume is also one of the manifestations of the difficulty in accurately predicting the purchase volume with volume procurement